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Sphingosine 1-phosphate receptor 2
A B S T R A C T
Skeletal muscle tissue retains a remarkable regenerative capacity due to the activation of resident stem cells that
in pathological conditions or after tissue damage proliferate and commit themselves into myoblasts. These im-
mature myogenic cells undergo differentiation to generate new myofibers or repair the injured ones, giving a
strong contribution to muscle regeneration. Cytokines and growth factors, potently released after tissue injury
by leukocytes and macrophages, are not only responsible of the induction of the initial inflammatory response,
but can also affect skeletal muscle regeneration. Growth factors exploit sphingosine kinase (SK), the enzyme that
catalyzes the production of sphingosine 1-phosphate (S1P), to exert their biological effects in skeletal muscle. In
this paper we show for the first time that bradykinin (BK), the leading member of kinin/kallikrein system, is able
to induce myogenic differentiation in C2C12 myoblasts. Moreover, evidence is provided that SK1, the specific
S1P-transporter spinster homolog 2 (Spns2) and S1P⁠2 receptor are involved in the action exerted by BK, since
pharmacological inhibition/antagonism or specific down-regulation significantly alter BK-induced myogenic dif-
ferentiation. Moreover, the molecular mechanism initiated by BK involves a rapid translocation of SK1 to plasma
membrane, analyzed by time-lapse immunofluorescence analysis. The present study highlights the role of SK1/
Spns2/S1P receptor 2 signaling axis in BK-induced myogenic differentiation, thus confirming the crucial involve-
ment of this pathway in skeletal muscle cell biology.
1. Introduction
Skeletal muscle retains a remarkable regenerative capacity that is
responsible for tissue repair. Skeletal muscle regeneration is character-
ized by an early and transient phase of inflammation that occurs in in-
jured tissue to ensure the removal of dead cells and debris [1–4]. In the
damaged microenvironment resident quiescent stem cells, called satel-
lite cells, become activated, proliferate and migrate towards the site of
the lesion, where they differentiate and fuse with each other or with
injured myofibers in order to repair the tissue [5]. Both resident and
infiltrating cells release soluble factors that affect muscle regeneration,
however, their exact effects on muscle recovery remain unknown. A
deeper knowledge of the mechanisms underlying skeletal muscle regen-
eration becomes crucial to identify possible innovative interventions to
efficaciously treat skeletal muscle diseases.
Cytokines and growth factors, produced and released after damage
by the injured tissue or by infiltrating leukocytes and macrophages,
are not only responsible for the generation/amplification of the ini-
tial inflammatory response, but also affect skeletal muscle regenera-
tion [4,6–8]. A role for the nonapeptide bradykinin (BK), the lead-
ing member of kinin/kallikrein system, in skeletal muscle vasodila-
tion is well established during contraction, when the peptide is ac-
tively released [9,10]. BK exerts its biological action after the liga-
tion to two distinct GPCR, named bradykinin B1 receptor (B1R) and
bradykinin B2 receptor (B2R) based on their distinct pharmacology
[11]. B2R subtype was found to
Abbreviations: SK, Sphingosine kinase; S1P, sphingosine 1-phosphate; BK, bradykinin; Spns2, spinster homolog 2; S1P⁠2, S1P receptor 2; B1R, bradykinin B1 receptor; B2R, bradykinin
B2 receptor; SPL, sphingosine 1-phosphate lyase; MyHC, skeletal fast myosin heavy chain.
⁎ Corresponding author at: Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università di Firenze, Viale GB Morgagni 50, 50134 Firenze, Italy.
Email address: francesca.cencetti@unifi.it (F. Cencetti)
1 Present address: Dipartimento di Scienze della Salute Umana, Università di Firenze, Viale Pieraccini 6 ‐ 50139 Firenze, Italy.
2 These authors equally contributed to this work.
https://doi.org/10.1016/j.cellsig.2018.02.001












G. Bruno et al. Cellular Signalling xxx (2018) xxx-xxx
be constitutively expressed in myocytes, while B1R is barely detectable
in normal healthy skeletal muscle, being induced after injury [9,12–15].
The molecular mechanism of BK action improve oxygen delivery [16].
In addition, in skeletal muscle BK is involved in nutrient disposal, since
it has been shown that the peptide enhances insulin signal and potenti-
ates insulin-stimulated glucose uptake through the B2R in cultured my-
oblasts [17]. Moreover, genetic polymorphism for B2R correlates with
skeletal muscle performance, muscle strength or size [18]. Finally, BK is
degraded by ACE and hence it is inversely linked with the angiotensin
II system, which plays a major role in skeletal muscle wasting and sar-
copenia [19].
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid gener-
ated by sphingomyelin catabolism, physiologically present in plasma
and serum, capable of regulating multiple cellular processes, including
proliferation and survival, cell motility and differentiation [20]. S1P is
synthesized from sphingosine through the ATP-dependent phosphoryla-
tion catalyzed by sphingosine kinase 1 (SK1) or 2 (SK2), which are acti-
vated by various stimuli, and reversibly degraded by specific S1P phos-
phatases and non-specific lipid phosphate phosphatases or irreversibly
cleaved by S1P lyase (SPL) [21]. The sphingolipid can exert its function
as an intracellular messenger, even if it acts mainly as ligand of specific
receptors (S1P⁠1–5) [22], after its release via specific and unspecific trans-
porters, spinster homolog 2 (Spns2) and ATP-binding cassette (ABC)
family members, respectively [23]. The signaling pathways downstream
the different S1P receptors can influence many biological processes,
such as angiogenesis, immune response, tumorigenesis and embryonic
development [24]. Of note, the biological role exerted by S1P signal-
ing axis in skeletal muscle has been described in literature. Indeed, the
bioactive sphingolipid stimulates proliferation of satellite cells and cell
motility [25], whereas it behaves as pro-myogenic [26] and anti-moto-
genic [27] cue in murine myoblasts. Experimental evidence has been
provided that many growth factors affecting skeletal muscle regenera-
tion in physiological or pathological conditions require the so-called in-
side-out S1P signaling [28]. For this reason, the regulation of S1P-syn-
thesizing enzymes becomes crucial for the modulation of S1P levels. In
this regard, PDGF and IGF1 exploit SK activation and S1P receptor en-
gagement, to exert their biological actions towards a reduced prolifera-
tion/enhanced cell motility and differentiation, respectively [29,30]. A
complex cross talk between TGFβ and S1P signaling axis has also been
highlighted, that accounts for the detrimental pro-fibrotic and pro-apop-
totic effects of the cytokine [31,32].
In this study we have identified BK as promyogenic cue in C2C12
myoblasts. BK-induced myoblast differentiation has been found to rely
on SK1 translocation to plasma membrane. Moreover, the specific trans-
porter Spns2 and S1P⁠2 engagement appear to be required for the biolog-
ical response of BK. The present results contribute to the characteriza-
tion of the physiological action of pro-inflammatory cue BK on skeletal
muscle regeneration, confirming at the same time the crucial role of S1P
inside-out signaling in skeletal muscle cell biology.
2. Materials and methods
2.1. Materials
Biochemicals, TRI Reagent® RNA Isolation Reagent, cell culture
reagents, protease inhibitor cocktail, bovine serum albumin (BSA), mon-
oclonal anti-fast skeletal muscle myosin heavy chain (MyHC, clone
MY-32), bradykinin (BK), mouse skeletal muscle C2C12 cells, Dulbec-
co's modified Eagle's medium (DMEM), Dulbecco's modified phos-
phate-buffered saline (DPBS) and Fetal calf serum (FCS) were purchased
from Sigma-Aldrich (St. Louis, MO). Pharmacological inhibitors of SKs
(VPC96091 and VPC96047) were kindly provided by Prof. K. Lynch,
University of Virginia, USA. pcDNA3 plasmid encoding B2R was kindly
provided by Dr. Andree Blaukat (formerly University of Heidelberg,
Germany). GFP-SK1-S225A encoding plasmid was kindly provided by
Stuart Pitson University of South Australia. The specific S1P⁠1/3 antag-
onist, VPC23019, and the selective S1P⁠2 antagonist, JTE013, were ob-
tained from Avanti Polar Lipids (Alabaster, AL, USA). Short interfer-
ing RNA (siRNA) duplexes targeting specific gene of interest such as
mouse SK1 (SASI_Mm01_00033983 and SASI_Mm01_00033984), mouse
SK2 (SASI_Mm01_00050883 and SASI_Mm01_00050884), mouse S1P⁠2
(SASI_Mm01_00082880 and SASI_Mm01_00082881) mouse Spns2
(EMU148461) and scrambled (SCR)-siRNA (Mission Universal Negative
control no. 1) were from Sigma-Proligo (The Woodlands, TX, USA).
Lipofectamine RNAiMAX® Transfection Reagent and all reagents and
probes used to perform real-time PCR were obtained from Life Tech-
nologies (Carlsbad, CA, USA). SK2 (N-terminal region) rabbit polyclonal
and SK1 (central region) rabbit polyclonal antibodies were purchased
from ECM Biosciences LLC (Versailles, KY USA). Secondary antibod-
ies conjugated to horseradish peroxidase, monoclonal anti-β-actin and
monoclonal anti-myogenin antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-caveolin-3 an-
tibody was from BD Biosciences Transduction Laboratories (Lexington,
KY, USA). Enhanced chemiluminescence (ECL) reagents were obtained
from GE Healthcare Europe GmbH (Milan, Italy). Fluorescein-conju-
gated anti-mouse secondary antibody and Vectashield® mounting
medium were purchased from Vector Laboratories (Burlingame, CA,
USA).
2.2. Cell culture
Murine C2C12 myoblasts were maintained in DMEM containing 10%
FCS, 2mM l-glutamine, 100μg/ml streptomycin and 100U/ml penicillin
at 37°C in 5% CO⁠2. For myogenic differentiation, cells were seeded
in p35 and when 90% confluent, the proliferating medium was re-
placed with DMEM without serum supplemented with 1mg/ml BSA and
incubated in the presence or absence of 1μM BK for 24 or 48h. In
some of the experiments, cells were pre-treated with 1μM JTE013, 1μM
VPC23019, 5μM VPC96047 or 5μM VPC96091, 30min before agonist
stimulation.
2.3. Cell transfection
For siRNA transfection, C2C12 cells were transfected with Lipofect-
amine RNAi-MAX according to the manufacturer's instructions. Briefly,
Lipofectamine RNAiMAX was incubated with siRNA in DMEM without
serum and antibiotics at room temperature for 20min, and afterwards
the lipid/RNA complexes were added with gentle agitation to C2C12
cells to a final concentration of 50nM in serum containing DMEM. Af-
ter 24h, cell medium was changed with serum-free DMEM containing
1mg/ml BSA and then used for the experiments within 48h from the
beginning of the transfection. The specific gene knockdown was evalu-
ated by real-time PCR.
For live cell imaging fluorescence experiments, C2C12 cells were
transiently co-transfected with plasmids encoding for bradykinin B2 re-
ceptor (B2R) and GFP-SK1 or GFP-SK1-S225A using Lipofectamine®
2000 Reagent according to the manufacturer's instructions. Transfec-
tion with GFP-SK1 or GFP-SK1-S225A plasmids has been previously de-
scribed [33]. Briefly, cells were seeded onto 8-well poly-L-lysin-coated
glass coverslips, and then transfected with a total amount of 0,5μg
of plasmid DNA per well. After 24h, transfection medium was re-
placed with proliferating medium for other 24h. Cells were than starved
overnight before experiments. Transfection efficiency for GFP-SK1 and
GFP-SK1-S225A was analyzed by fluorescence microscopy of living
cells, and cells were used for the experiments within 72h from the be-
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2.4. Western blot analysis
C2C12 myoblasts after 24 and 48h of BK treatment were collected
and lysed 30min at 4°C in a buffer containing 50mM Tris, pH7.5,
120mM NaCl, 1mM EDTA, 6mM EGTA, 15mM Na⁠4P⁠2O⁠7, 20mM NaF,
1% Nonidet and protease inhibitor cocktail. Then lysates were cen-
trifuged at 10^4×g, 15min 4°C and 15μg of protein from total cell
lysates were used to perform a SDS-polyacrylamide gel electrophoresis
and Western blot (WB) analysis [26] in order to evaluate the different
expression of SK1, SK2, the myogenic differentiation markers, myogenin
and caveolin-3. PDVF membranes were incubated overnight with the
primary antibodies at 4°C and then with specific secondary antibodies
for 1h at room temperature. Binding of the antibodies with the specific
proteins has been detected by chemiluminescence.
2.5. Quantitative real-time RT-PCR
Total RNA from C2C12 myoblasts was extracted using a TRI
Reagent® RNA Isolation Reagent. Then, 1μg of RNA was reverse tran-
scribed using the high capacity cDNA reverse transcription kit (Ap-
plied Biosystems). TaqMan gene expression assays were used to per-
form real-time PCR in order to quantify SK1, SK2, S1P⁠2 and Spns2
mRNA expression. Each measurement was carried out in triplicate, us-
ing the automated ABI Prism 7700 Sequence Detector System (Applied
Biosystems) as described previously [31], by simultaneous amplification
of the target sequence (SK1 Mm00448841_g1, SK2 Mm00445021_m1,
S1P⁠2 Mm01177794_m1, Spns2 Mm01249328_m1; Applied Biosystems)
together with the housekeeping gene 18S rRNA. The analysis of the re-
sults was performed by ABI Prism Sequence Detection System software,
version 1.7 (Applied Biosystems). The 2^(-ΔΔCt) method was applied as
a comparative method of quantification [34], and data were normalized
to ribosomal 18S RNA expression.
2.6. Immunostaining and fluorescence microscopy
C2C12 myoblasts were seeded on pre-coated (2% gelatin) micro-
scope slides. After 24h the proliferating medium was replaced with
DMEM without FCS supplemented with 1mg/ml BSA and cells were
treated or not with 1μM BK. In some of the experiments, cells were
pre-treated with 5μM VPC96047 or 5μM VPC96091, 30min before ag-
onist stimulation. After 96h, cells were fixed in 2% paraformaldehyde
in PBS for 20min and then permeabilized in 0.1% Triton X-100–PBS for
30min. For blocking step cells were kept in agitation with 3% BSA in
DPBS for 1h. Then, C2C12 were incubated with anti-MyHC antibody
for 2h and fluorescein-conjugated anti mouse secondary antibody for
1h. Finally, cells were incubated with propidium iodide solution (0.5μM
PI in 0.3M NaCl, 0.03M sodium citrate, pH7.0) for 15min for nuclear
staining. Images were taken using a Leica SP5 laser scanning confocal
microscope with 63× objective.
2.7. Live cell imaging
C2C12 cells were seeded onto 8-well poly-L-lysin-coated glass cov-
erslips and co-transfected as described above. During the live imaging
acquisition, C2C12 cells were incubated in HBSS (containing 118 mM
NaCl, 5mM KCl, 1mM CaCl⁠2, 1mM MgCl⁠2, 5mM glucose, and 15mM
HEPES, pH7.4) and treated with 1μM BK. Excitation laser lines/emis-
sion filter were set up at 488/505nm for GFP. Fluorescence images were
obtained using a Zeiss LSM510 inverted confocal laser scanning mi-
croscope and a Plan-Apochromat 63×1.4 oil immersion objective (Carl
Zeiss MicroImaging GmbH, Göttingen, Germany).
The translocation half-time was calculated by measuring the de-
crease of fluorescence intensity in the cytosolic region and fitting of an
exponential function to this decay [33].
2.8. Determination of sphingolipid concentrations by high-performance
liquid chromatography tandem mass spectrometry
Cell pellets were suspended with 100μl extraction buffer (citric
acid 30mM, disodium hydrogen phosphate 40mM) and 20μl of the
internal standard solution containing sphingosine-d7, sphinganine-d7
(30ng/ml each), sphingosine-1-phosphate-d7 (40ng/ml, all avanti po-
lar lipids, Alabaster, USA). The mixture was extracted once with 500μl
methanol/chloroform/hydrochloric acid (15:83:2, v/v/v). The lower or-
ganic phase was evaporated at 45°C under a gentle stream of nitrogen
and reconstituted in 50μl of methanol.
Analytes were separated using an Agilent 1260 series binary pump
(Agilent technologies, Waldbronn, Germany) equipped with a Kinetex
EVO C18 HPLC column (50mm×2.1mm ID, 1.7μm particle size, 100Å
pore size; Phenomenex, Aschaffenburg, Germany). The column temper-
ature was 55°C. The HPLC mobile phases consisted of water with 0.5%
formic acid and (mobile phase A) and acetonitrile/isopropanol/acetone
(50:30:20, v/v/v) with 1% formic acid (mobile phase B). For separa-
tion, a gradient program was used at a flow rate of 0.3ml/min. The to-
tal running time was 7.5min and the injection volume was 20μl. After
every sample, ethanol was injected for washing the column. The MS/
MS analyses were performed using a triple quadrupole mass spectrome-
ter 5500QTRAP (Sciex, Darmstadt, Germany) equipped with a Turbo V
Ion Source operating in positive electrospray ionization mode. The MS
parameters were set as follows: Ionspray voltage 4500V, source temper-
ature 500°C, curtain gas 35psi, collision gas 6psi, nebulizer gas 50psi
and heating gas 70psi. The analysis was done in Multiple Reaction Mon-
itoring (MRM) mode.
Data Acquisition was done using Analyst Software V 1.6 and quan-
tification was performed with MultiQuant Software V 3.0 (both Sciex,
Darmstadt, Germany), employing the internal standard method (isotope
dilution mass spectrometry). Variations in accuracy of the calibration
standards were less than 15% over the whole range of calibration, ex-
cept for the lower limit of quantification, where a variation in accuracy
of 20% was accepted.
2.9. Glucose uptake assay
To determine glucose uptake, C2C12 cells were seeded in 6-well
plates, serum-starved for 18h and then stimulated with 1 and 10μM
BK and 10nM insulin for 60min. Briefly, following BK or insulin chal-
lenge, a buffered solution (140mM NaCl, 20mM Hepes, 2.5mM MgSO⁠4,
1mM CaCl⁠2 and 5mM KCl, pH7,4) containing 1μCi of ⁠3H–glucose
(1mCi/0.1mmol) was added to each well and glucose uptake was al-
lowed at 37°C for 15min. Cells were then washed with cold PBS and
lysed in 0.1M NaOH. Incorporated radioactive glucose was quantified
by liquid scintillation counting of aliquots of the lysates, and normalized
on protein content.
2.10. Statistical analysis
ImageJ software was used to perform densitometric analysis of the
Western Blot bands. The images obtained in live fluorescence were
edited using the programs LSM Image Browser or ZEN (www.zeiss.com/
micro). Graphical representations were obtained by GraphPad Prism 5.0
(GraphPad Software, San Diego, CA). Statistical analysis was performed
using Student's t-test, one-way and two-way ANOVA analysis of variance
followed by Bonferroni's post-hoc test. Asterisks show statistical signifi-
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3. Results
In order to study the possible action of BK on myogenic differentia-
tion, a concentration-response effect of BK on myogenic marker expres-
sion was analyzed in confluent serum starved C2C12 myoblasts, after
the addition of different concentrations of BK for 24h. Total cell lysates
were subjected to western blot analysis to measure the relative content
of myogenic marker myogenin. As reported in Fig. 1A, 24h BK treat-
ment was capable of inducing myogenin expression in a dose-dependent
manner, being efficacious both at 1μM and 10μM concentration. Tak-
ing into consideration that myogenin is an early transcriptional myo-
genic marker, we then employed confocal immunofluorescence analysis
to quantify the expression of a later functional myogenic marker such
as myosin heavy chain (MyHC). The confocal microscopy images illus-
trated in Fig. 1B clearly demonstrate that 1μM BK potently enhanced
the expression of MyHC after three day-incubation and induced a more
mature phenotype in myotubes.
Moreover, with the specific aim to study glucose uptake by BK in
C2C12 myoblasts, we performed ⁠3H-glucose incubation for 15min af-
ter the stimulation with the peptide at 1 and 10μM for 60min. We es-
tablished that glucose uptake was not significantly affected by BK chal-
lenge, whereas it was significantly increased after 10nM insulin stim-
ulation (Fig. 2), ruling out a role for BK in glucose disposal in C2C12
myoblasts.
Since SK1/S1P axis exerts a pro-myogenic action in murine my-
oblasts [35], the involvement of this signaling pathway in BK-medi-
ated effect was studied. For this reason, a pharmacological approach
was used to inhibit SK activity and analyze its involvement in BK-in-
duced myogenic differentiation. The treatment of C2C12 myoblasts with
specific SK1 inhibitor VPC96091 and pan-inhibitor VPC96047 for 18h
caused a dramatic decrease of S1P levels measured by high-performance
liquid chromatography tandem mass spectrometry (Fig. 3A). The block-
ade of SK1 by VPC96091 significantly decreased the expression of myo-
genin and the late myogenic marker caveolin-3 induced by 1μM BK
for 24 and 48h, respectively. On the other hand, the treatment with
VPC96047 potently reduced myogenin expression, whereas it affected
to a lesser extent caveolin-3 levels after BK challenge (Fig. 3B).
The involvement of SK in BK-mediated differentiation was further
studied by measuring the expression of MyHC to confirm the results
obtained by WB for myogenin and caveolin-3 expression. Immunoflu-
orescence analysis performed in three-day serum-starved murine my-
oblasts treated with 1μM BK after pre-treatment with VPC96091 (Fig.
4) showed that the expression of MyHC was significantly reduced by
SK1 inhibition, thus demonstrating that the enzyme is involved in BK-in-
duced myogenic differentiation. Pre-incubation with SK pan-inhibitor
VPC96047 less strongly inhibited MyHC expression.
To further establish the role exerted by each SK isoform, RNA in-
terference approach was used. Efficient and selective down-regulation
of SK1 (Fig. 5A and B) in myoblasts transfected with specific murine
SK1-siRNA, beside significantly reducing the basal level of myogenic
marker expression, abrogated BK-mediated myogenin and caveolin-3
expression, as illustrated in Fig. 5C. Conversely, specific SK2 down-reg-
ulation (Fig. 5A and B) did not alter the effect brought about by BK (Fig.
5C).
Then to dissect the molecular mechanism by which SK1 is involved
in BK action, we analyzed the effect of BK on SK1 intracellular localiza-
tion. Taking into account that the biological actions of BK are transmit-
ted by its B2 type receptor (B2R), being the B1R physiologically absent
[14–17], C2C12 myoblasts were co-transfected with B2R and GFP-SK1
(Fig. 6A) encoding plasmids. By immunofluorescence microscopy analy-
sis, we examined the effect of 1μM BK treatment showing that the
peptide was capable of inducing a rapid translocation of SK1 from cy
Fig. 1. Concentration-dependent effect of Bradykinin on myogenin expression in murine
myoblasts.A. Total cell lysates (15μg) of C2C12 cells stimulated with the indicated
concentration of BK for 24h, were subjected to western blotting to measure myogenin
expression. Blot is representative of three experiments with similar results. The effect of
1 and 10μM BK on myogenin expression, normalized to that of beta isoform of actin
(β-actin), was statistically significant by one-way Anova, followed by Bonferroni's post-hoc
test, P<0.05. B. Confocal immunofluorescence analysis was performed in three-days
serum-starved C2C12 cells in the presence or absence of 1μM BK, using anti-fast skeletal
muscle myosin heavy chain (MyHC) antibody, fluorescein-conjugated anti-mouse
secondary antibody and propidium iodide staining. The immunofluorescence images here
reported are representative of three independent experiment with each condition
performed in duplicate with similar results.
tosol to the plasma membrane. SK1 translocation to plasma membrane
was measured by time-lapse laser-scanning confocal microscopy. The
decrease of fluorescence in the cytosol after BK treatment was used to
calculate the translocation half-time of the enzyme that ranged between
4 and 7s (Fig. 6B), sustaining the view that the BK challenge provokes
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Fig. 2. Effect of Bradykinin on glucose uptake in murine myoblasts.C2C12 cells stimulated
with the indicated concentration of BK or 10nM insulin for 60min were incubated with
radiolabeled ⁠3H-glucose for 15min to measure glucose uptake. Data are mean±SEM
obtained from three independent experiment each performed in triplicate, and reported
as fold increase over control, set as 1. The effect of 10nM insulin on glucose uptake
was statistically significant compared to control untreated by one-way Anova followed by
Bonferroni's post-hoc test, *P<0.05.
Pitson and colleagues previously demonstrated that SK1 translo-
cation from the cytosol to plasma membrane is induced by Ser225
phosphorylation [36]. To analyze the contribution of Ser225 phospho-
rylation to SK1 translocation, the above-described experiments were
performed in C2C12 myoblasts co-transfected with plasmids encod-
ing for B2R and for the phosphorylation-defective mutant of hSK1,
GFP-SK1-S225A. Translocation half-time measured by fluorescence vari-
ation in the cytosol of GFP-SK1-S225A after BK treatment was unaltered
compared to GFP-SK1, suggesting that Ser225 phosphorylation was not
necessary to induce membrane translocation of the enzyme after BK
challenge (Fig. 6A and B).
Myogenic differentiation brought about by exogenously added S1P
in murine myoblasts has been reported to be accomplished through S1P⁠2
receptor engagement [26]. The possible involvement of S1P receptors
in BK mediated action was analyzed by using specific antagonists for
S1P1/3 VPC23019 or S1P⁠2 JTE013. The specific blockade of S1P⁠2 was
capable of abrogating BK-induced caveolin-3 and myogenin expression,
demonstrating that this receptor subtype is involved in the action mech-
anism of BK (Fig. 7). However S1P⁠1/3 blockade did not alter myogenin
expression, it slightly enhanced caveolin-3 basal level even if in a not
significant manner (Fig. 7).
The engagement of S1P⁠2 in BK-dependent differentiation was fur-
ther analyzed by RNA interference approach. Specific S1P⁠2 siRNA was
transfected in murine myoblasts to knockdown the expression of this
receptor subtype. S1P⁠2 downregulation, assessed by Real-Time PCR in
Fig. 8A, caused an impairment of BK-induced caveolin-3 and myogenin
expression as depicted in Fig. 8B, confirming the results obtained with
the pharmacological approach. Morphological analysis by optical mi-
croscopy was used to analyze the effect of BK on myogenic differen-
tiation in S1P⁠2-siRNA transfected skeletal muscle cells after four days
of serum deprivation. As shown in Fig. 8 , S1P⁠2 knocked-down murine
myoblasts were unable to differentiate towards mature myotubes in re-
sponse to 1μM BK, thus claiming a crucial role for this specific receptor
subtype in BK action.
The participation of both SK1 and S1P⁠2 in BK-induced myogenic ef-
fect could be explained via the “inside-out” mechanism of action, in
which S1P produced within the cell can be exported via S1P trans-
porters in order to act as ligand of S1P receptors. To address this issue,
RNA interference was used to investigate the role of the specific trans-
porter Spns2 in BK-dependent myogenic differentiation. The specific
down-regulation of Spns2, checked by Real-Time PCR in siRNA trans-
fected myoblasts (Fig. 9A), fully abrogated the augmented expression
of myogenin and caveolin-3 induced by BK at 24 and 48h, respectively
(Fig. 9B). These latter results clearly demonstrate that BK stimulates my-
oblast differentiation towards myotubes through the involvement of the
specific S1P transporter responsible for the export of the bioactive lipid
that acts in autocrine or paracrine manner.
4. Discussion
Skeletal muscle is a stable tissue that retains a good regenerative ca-
pacity, which is responsible for tissue repair after injury. Skeletal muscle
regeneration is characterized by an early phase of acute inflammation
that accounts for the clearance of dead cells and cell debris [37–40].
Soluble factors produced and released by resident and infiltrating cells,
constitute a microenvironment that affects later phases of skeletal mus-
cle regeneration, when the tissue is repaired by resident stem cell activa-
tion, proliferation and differentiation [41]. However, in chronic human
diseases such as dystrophies and other myopathies repeated cycles of
degeneration of newly formed myofibers progressively exhaust the stem
cell pool and, in association with chronic inflammation, cause persistent
tissue damage and fibrosis [42].
BK is a vasoactive nonapeptide that is involved in the maintaining of
circulation homeostasis, exerting its function mainly through its specific
binding to G protein coupled receptors inducible B1R and constitutive
B2R [43,44]. Within skeletal muscle, the peptide promotes an increase
of muscle blood flow and glucose uptake [16,17]. A role for BK in tissue
inflammation and vasodilatation, plasma extravasation has been exten-
sively addressed in literature [45]. During skeletal muscle contraction,
the rise of interstitial BK is relevant for the increase in blood flow and
vasodilation, improving oxygen delivery that meets the elevated oxygen
demand during exercise [10]. In inflammatory states, BK promotes both
the migration of inflammatory cells from blood to tissues and the activa-
tion of various tissue components such as macrophages [46]. However,
whether BK plays a role in skeletal muscle regeneration has not been yet
investigated.
In this study, satellite cell-derived murine cell line, C2C12 my-
oblasts, has been employed, which is extensively used as a model to
study skeletal muscle biology in vitro. These cells display a myogenic
behavior, differentiating into syncytial cells, known as myotubes. Here
we show for the first time that BK increases the myogenic differentia-
tion of myoblasts that was analyzed by using a molecular and morpho-
logical approach. On this basis, we can speculate that during skeletal
muscle regeneration BK, besides being released after a damage to af-
fect macrophage and lymphocyte recruitment, can also promote skele-
tal muscle repair by inducing the differentiation of myogenic precursor
cells. Intriguingly, a specific allelic polymorphism of B2R was associ-
ated with greater skeletal muscle metabolic efficiency in both athletes
and non-athletes [47] and with muscle hypertrophy [18]. Notably, ex-
periments aimed at measuring BK-induced glucose uptake showed that
the peptide did not significantly affect this process in C2C12 myoblasts.
Although this is not in agreement with previous results that identify a
role for BK in GLUT4 translocation and glucose uptake in different cell
models [48,49], it can be explained by the absence of GLUT4 in C2C12
cell line [50].
It is well established that several cytokines and growth factors modu-
late S1P signaling axis to exert their biological functions. In this regard,
it has been previously demonstrated that in murine myoblasts the recog-
nized pro-myogenic cue IGF1 acts via the involvement of SK/S1P⁠2 [29].
The molecular mechanism brought about by IGF1 implicates the rapid
translocation of both SK1 and SK2 to plasma membrane. Conversely, in
the present study, we show that BK action depends on the regulation
of SK1, since when the enzyme was inhibited or specifically down-regu-
lated by siRNA treatment, BK effect was potently reduced. Inhibition or
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Fig. 3. Role of SK1 in Bradykinin-induced myogenic differentiation of C2C12 myoblasts (I)A. Serum-starved C2C12 cells were treated with SK1 specific inhibitor (VPC96091) or SK
pan-inhibitor (VPC96047) for 6 and 18h and cell lysates were analyzed for S1P content by high-performance liquid chromatography tandem mass spectrometry as described in Materials
and Methods. Results are reported as mean±SEM of pmol S1P/10^6 cells. The effect of VPC96091 and VPC96047 on S1P levels was statistically significant by one-way Anova, followed
by Bonferroni's post-hoc test, *P<0.05, **P<0.01.B. C2C12 cells were stimulated with 1μM BK for 24 and 48h after the treatment with SK1 specific inhibitor (VPC96091) or SK
pan-inhibitor (VPC96047) for 30min, and cell lysates were subjected to western blotting to measure myogenic differentiation markers myogenin and caveolin-3 (cav-3), normalized to
the expression of non-muscle beta isoform of actin (β-actin). Blot is representative of three experiments with similar results. The effect of VPC96091 and of VPC96047 on BK-induced
myogenin expression was statistically significant by two-way Anova, followed by Bonferroni post-hoc test, *P<0.05. The effect of VPC96091 on BK-induced caveolin-3 expression was
statistically significant by two-way Anova, followed by Bonferroni post-hoc test, *P<0.05.
It has been previously demonstrated that SK1 activation requires
phosphorylation and translocation to the plasma membrane [36], where
the substrate sphingosine is located. Results presented here, however,
clearly show that phosphorylation is not necessary for B⁠2 receptor-in-
duced membrane translocation of SK1 in C2C12 myoblasts, since the
translocation half-time of the GFP-SK1-S225A mutant after BK challenge
was similar to that of the wild-type enzyme. Phosphorylation-indepen-
dent translocation of SK1 has been shown before in HEK-293 cells for
the M⁠3 muscarinic receptor, which also is a G⁠q-coupled receptor [33].
Thus, it might be speculated that G⁠q-mediated activation of SK1 involves
phosphorylation-independent signaling pathways, however, it cannot be
excluded that phosphorylation of SK1, while dispensable for transloca-
tion, is still necessary for its activation.
During acute inflammation in response to injury or invading
pathogens cytokines, BK and TNFα among others, are released to mo-
bilize effector cells and molecules to the site of injury and to promote
tissue healing. Low-dose TNFα is physiologically involved in the adap-
tation of healthy skeletal muscle to intensive exercise by promoting the
differentiation of muscle progenitors [51,52]. The here reported biolog-
ical action of BK on myoblast differentiation is similar to the effect of
low-dose TNFα in the biology of murine myoblasts, where it has been
previously demonstrated that the cytokine exerts a pro-differentiating
effect through the involvement of SK1/S1P⁠2 axis [53].
The observation that BK-induced myogenic effect is dependent on
S1P⁠2-engagement is in accordance with previous findings indicating that
S1P⁠2 is responsible for transducing the pro-differentiating action of ex-
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Fig. 4. Role of SK1 in Bradykinin-induced myogenic differentiation of C2C12 myoblasts (II)Immunofluorescence analysis of the myogenic marker myosin heavy chain (MyHC) was
performed in three day-differentiated myoblasts in the presence or absence of 1μM after the treatment with SK1 specific inhibitor VPC96091 and SK pan-inhibitor VPC96047, using
a specific mouse anti-myosin heavy chain (MyHC) antibody, fluorescein-conjugated anti-mouse secondary antibody and propidium iodide staining (images are representative of three
independent experiments).
pothesized that the transactivation of S1P⁠2 by BK occurs via the
well-known S1P inside-out signaling, that implicates the involvement
of an S1P transporter. Indeed, we found out that Spns2 is expressed in
murine myoblasts in agreement with a previous publication [54] and
that, the pro-differentiating effect of BK was completely abolished when
Spns2 was specifically down-regulated, thus implicating that S1P export
is necessary in BK-dependent action.
Notably, we observed that SK1 blockade or knock-down were capa-
ble of dramatically decreasing basal myogenic markers expression, in
agreement with the critical role of SK1 in myogenic differentiation [35].
However, the same effects were not observed targeting Spns2 or S1P2,
maybe due to the spatially and temporally restricted engagement of the
transporter and the receptor by BK to transmit its specific pro-myogenic
effect.
Intensive research aimed at addressing the molecular mechanisms
of skeletal muscle regeneration will feasibly identify innovative targets
to treat acute muscle injuries and chronic muscle diseases. These find-
ings may have relevant implications for therapeutic purposes, since a
treatment for such skeletal muscle diseases is not yet available.
5. Conclusion
The here reported results describe for the first time a pro-myogenic
effect of BK in murine myoblasts. Moreover, BK has been here shown to
be capable of inducing a rapid SK1 translocation to plasma membrane
that is required for BK-induced differentiation of myoblasts.
The presented data support the hypothesis that a precise regulation
of S1P inside-out signaling takes place in the pro-myogenic action of
BK. In particular, this pathway involves Spns2 transporter and the S1P⁠2
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Fig. 5. Role of SK1 in Bradykinin-induced myogenic differentiation of C2C12 myoblasts (III)A. Real-time PCR analysis was performed to assess the down-regulation of SK1 and SK2 mRNA
in SK1- or SK2-siRNA transfected myoblasts. Results are reported as mean±SD of three independent experiments performed in triplicate, using the 2^(-ΔΔCt) method as described in
Materials and Methods section. The effect of siRNA transfection on SK1 and SK2 down-regulation was statistically significant by student's t-test, **P<0.01. ***P<0.001B. Cell lysates
from SK1- or SK2-siRNA transfected C2C12 cells were subjected to western blotting to measure both SK1 and SK2. Results were checked for the expression of non-muscle beta isoform
of actin (β-actin). Blot is representative of three experiments with similar results.C. Cell lysates from SK1- or SK2-siRNA transfected C2C12 cells, incubated with 1μM BK for 24 and 48h,
were subjected to western blotting to measure myogenic differentiation markers myogenin and caveolin-3, respectively. Results were normalized to the expression of non-muscle beta
isoform of actin (β-actin) and reported as mean±SEM, fold change over control, set as 1. Blot is representative of three experiments with similar results. The effect of SK1 down-regulation
on BK-induced myogenic differentiation was statistically significant by two-way Anova, followed by Bonferroni's post-hoc test, *P<0.05.
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Fig. 6. Bradykinin-induced SK1 translocation in C2C12 myoblasts.The cells had been transfected with the bradykinin B2 receptor and either GFP-SK1 wild-type or GFP-SK1-S225A.
A, Representative experiments showing transfected C2C12 myoblasts before and 1min after addition of 1μM bradykinin. The traces show the corresponding time courses of cytosolic
fluorescence intensity (solid lines) and the fitted exponential curves (dashed lines). B, Translocation half- time of GFP-SK1 wild-type and GFP-SK1-S225A in C2C12 myoblasts stimulated
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Fig. 7. S1P⁠2 is involved in Bradykinin-mediated myogenic differentiation of C2C12 myoblasts (I)C2C12 myoblasts were stimulated with 1μM BK for 24h after the treatment with S1PR
specific antagonists (VPC23019 or JTE013) and cell lysates were subjected to western blotting to measure myogenic differentiation markers myogenin and caveolin-3, normalized to the
expression of non-muscle β-actin. Blot is representative of three experiments with similar results. The effect of JTE013 on BK-induced myogenic differentiation was statistically significant
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Fig. 8. S1P⁠2 is involved in Bradykinin-mediated myogenic differentiation of C2C12 myoblasts (II)A. Real-time PCR analysis was performed to assess the down-regulation of S1P⁠2 mRNA
in S1P⁠2-siRNA transfected myoblasts. Results are reported as mean±SD of three independent experiments performed in triplicate, using the 2^(-ΔΔCt) method as described in Materials
and Methods section. The effect of siRNA transfection on S1P⁠2 down-regulation was statistically significant by student's t-test, **P<0.01.B. S1P⁠2-siRNA and SCR-siRNA transfected C2C12
myoblasts were treated with 1μM BK for 24h and 48h and cell lysates were analyzed by western blotting to measure myogenic differentiation markers, myogenin and caveolin-3. Results
were normalized to the expression of non-muscle β-actin. Blot is representative of three experiments with similar results.C. Optical microscopy images of myoblasts transfected with
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Fig. 9. Bradykinin-mediated myogenic differentiation is dependent on Spns2 expressionA. Real time PCR analysis was performed to assess the down-regulation of Spns2 mRNA in
SPNS2-siRNA transfected myoblasts. The effect of siRNA transfection on Spns2 down-regulation was statistically significant by student's t-test, *P<0.05.B. Spns2-siRNA and SCR-siRNA
transfected C2C12 myoblasts were treated with 1μM BK for 24h and 48h and cell lysates were analyzed by western blotting to measure myogenic differentiation markers, myogenin and
caveolin-3. Results were normalized to the expression of non-muscle β-actin, and are reported as mean±SEM, fold change over control. Blot is representative of three experiments with
similar results.
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